Femoral Bone Metastasis is a Poor Prognostic Factor in EGFR-TKIs-treated Patients with -mutated Non-small-cell Lung Cancer: a Retrospective, Multicenter Cohort Study

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2024 Dec 23

PMID 39712073

Authors

Ichidai Tanaka

Kazumi Hori

Junji Koyama

Soei Gen

Masahiro Morise

Yuta Kodama

Akira Matsui

Ayako Miyazawa

Tetsunari Hase

Yoshitaka Hibino

Toshihiko Yokoyama

Tomoki Kimura

Norio Yoshida

Mitsuo Sato

Makoto Ishii

Affiliations

Soon will be listed here.

Abstract

Background: ()-mutant non-small-cell lung cancers (NSCLCs) have higher frequencies of bone metastases than those of wild type; however, the metastatic pattern and influence on clinical outcome remain unclear.

Objectives: To analyze the association between bone metastatic sites and the clinical efficacy of the first-, second-, and third-generation EGFR-tyrosine kinase inhibitors (TKI), in these patients.

Design: Retrospective multicenter cohort study.

Methods: The clinical data of patients with advanced-NSCLC harboring mutation, who were treated by EGFR-TKIs as first-line treatment at five medical institutions ( = 411), were retrospectively assessed for bone metastatic sites, overall survival (OS), and progression-free survival (PFS).

Results: Bone metastases were found in 41.1% of the patients at diagnosis, including 13.1%, 8.0%, and 20.0 for single, double, and multiple lesions (⩾3), respectively. The vertebra (76.3%) and pelvis (60.9%) were the most frequent metastatic sites. Femoral-, sternum-, and scapula-metastases were remarkably increased in the patients with multiple-bone metastases. In the -mutant NSCLC patient treated with osimertinib, both the OS and the PFS of the patients with femoral bone metastasis were significantly shorter than those of the patients without femoral bone metastasis (OS: not reached vs 12.1 months, < 0.0001; and PFS: 17.2 vs 9.3 months, < 0.0018). Furthermore, a multivariable Cox regression analysis, including several poor prognostic factors, such as mutation and liver metastasis, demonstrated that femoral bone metastasis was a statistically independent predictor of OS.

Conclusion: Femoral bone metastasis is associated with poor survival of -mutant NSCLC patients who were treated with EGFR-TKIs, including osimertinib, and is an independent prognostic factor of OS.

References

Tanaka I, Morise M, Kodama Y, Matsui A, Ozawa N, Ozone S . Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung Cancer. 2018; 127:169-171. DOI: 10.1016/j.lungcan.2018.11.018. View

Dormieux A, Mezquita L, Cournede P, Remon J, Tazdait M, Lacroix L . Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. Eur Radiol. 2020; 30(9):5021-5028. DOI: 10.1007/s00330-020-06784-y. View

Park K, Tan E, OByrne K, Zhang L, Boyer M, Mok T . Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X. View

Wu Y, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3. View

De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello M, Aldinucci D . The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2007; 214(3):559-67. DOI: 10.1002/jcp.21260. View

Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T . Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. J Thorac Oncol. 2020; 16(2):205-215. DOI: 10.1016/j.jtho.2020.10.006. View

Landi L, DInca F, Gelibter A, Chiari R, Grossi F, Delmonte A . Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2019; 7(1):316. PMC: 6868703. DOI: 10.1186/s40425-019-0793-8. View

Kuijpers C, Hendriks L, Derks J, Dingemans A, van Lindert A, van den Heuvel M . Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer. Lung Cancer. 2018; 121:76-81. DOI: 10.1016/j.lungcan.2018.05.006. View

Tanaka I, Morise M, Miyazawa A, Kodama Y, Tamiya Y, Gen S . Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. Clin Lung Cancer. 2020; 21(3):273-280.e4. DOI: 10.1016/j.cllc.2020.01.011. View

10.

Doebele R, Lu X, Sumey C, Maxson D, Weickhardt A, Oton A . Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012; 118(18):4502-11. PMC: 3370097. DOI: 10.1002/cncr.27409. View

11.

Higuchi T, Sugisawa N, Park J, Sun Y, Zhu G, Yamamoto N . Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival. Transl Oncol. 2020; 13(10):100826. PMC: 7356269. DOI: 10.1016/j.tranon.2020.100826. View

12.

Tsuya A, Kurata T, Tamura K, Fukuoka M . Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 2007; 57(2):229-32. DOI: 10.1016/j.lungcan.2007.03.013. View

13.

Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M . Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol. 2007; 1(6):571-6. View

14.

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

15.

Weiss R, Wedin R . Surgery for skeletal metastases in lung cancer. Acta Orthop. 2011; 82(1):96-101. PMC: 3230004. DOI: 10.3109/17453674.2011.552779. View

16.

Al Bakir M, Huebner A, Martinez-Ruiz C, Grigoriadis K, Watkins T, Pich O . The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023; 616(7957):534-542. PMC: 10115651. DOI: 10.1038/s41586-023-05729-x. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Bae H, Lee S, Kim T, Kim D, Yang S, Wu H . Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer. 2012; 77(3):572-7. DOI: 10.1016/j.lungcan.2012.05.094. View

19.

Sun J, Ahn J, Lee S, Kim J, Lee J, Park Y . Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer. 2010; 71(1):89-93. DOI: 10.1016/j.lungcan.2010.04.003. View

20.

Hendriks L, Smit E, Vosse B, Mellema W, Heideman D, Bootsma G . EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?. Lung Cancer. 2014; 84(1):86-91. DOI: 10.1016/j.lungcan.2014.01.006. View